Ainos (NASDAQ:AIMD – Get Free Report) issued its earnings results on Monday. The company reported ($0.62) earnings per share (EPS) for the quarter, FiscalAI reports. Ainos had a negative net margin of 11,912.10% and a negative return on equity of 160.55%.
Ainos Stock Performance
Shares of NASDAQ:AIMD opened at $1.45 on Tuesday. The firm’s 50 day simple moving average is $1.88 and its 200 day simple moving average is $1.74. Ainos has a fifty-two week low of $1.26 and a fifty-two week high of $4.50. The company has a market capitalization of $12.35 million, a price-to-earnings ratio of -0.50 and a beta of 2.46. The company has a debt-to-equity ratio of 1.58, a current ratio of 0.55 and a quick ratio of 0.50.
Insider Activity at Ainos
In other Ainos news, major shareholder Carbon Nano Technology Taiwan sold 41,000 shares of the stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $2.36, for a total value of $96,760.00. Following the sale, the insider directly owned 948,925 shares in the company, valued at approximately $2,239,463. This trade represents a 4.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Chun-Jung Tsai sold 27,718 shares of Ainos stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $1.87, for a total transaction of $51,832.66. Following the transaction, the director directly owned 658,199 shares in the company, valued at approximately $1,230,832.13. This represents a 4.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders bought 7,500 shares of company stock worth $15,435 and sold 179,788 shares worth $359,247. Corporate insiders own 9.79% of the company’s stock.
Institutional Trading of Ainos
Analyst Upgrades and Downgrades
Separately, Weiss Ratings raised shares of Ainos from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, May 26th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.
Check Out Our Latest Stock Report on AIMD
Ainos Company Profile
Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.
The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format.
See Also
- Five stocks we like better than Ainos
- Tyson Foods Offers a Meaty Opportunity for Income Investors
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
Receive News & Ratings for Ainos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ainos and related companies with MarketBeat.com's FREE daily email newsletter.
